<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610116</url>
  </required_header>
  <id_info>
    <org_study_id>C007-CL-106002</org_study_id>
    <nct_id>NCT00610116</nct_id>
  </id_info>
  <brief_title>Electronic Repositioning With Acuity and Easytrak Leads</brief_title>
  <acronym>ERACE</acronym>
  <official_title>Electronic Repositioning With Acuity and Easytrak Leads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate appropriate performance of Electronic Repositioning™ (ER) in the clinical routine,&#xD;
      cumulative incidence of phrenic nerve stimulation (PNS) &amp; success rates of Electronic&#xD;
      Repositioning (ER) to remove it, various incl. left ventricular pacing (LVP) thresholds and&#xD;
      PNS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar leads for left ventricular pacing (LVP) such as the newly available ACUITY™ or the&#xD;
      standard EASYTRAK™ II and EASYTRAK™ III leads from GUIDANT in combination with suitable&#xD;
      devices for cardiac resynchronization therapy (CRT) allow for the non-invasive programming of&#xD;
      different Left Ventricular Pacing (LVP) configurations. Hence, this Electronic Repositioning&#xD;
      (ER) may help physicians to overcome problems in cardiac resynchronization therapy (CRT) such&#xD;
      as ineffective biventricular pacing, high Left Ventricular Pacing (LVP) thresholds and&#xD;
      phrenic nerve stimulation (PNS) without the need for an additional patient's operation to&#xD;
      reposition LV leads. The ERACE study it a multi-center, prospective, non-randomized clinical&#xD;
      study to document and evaluate appropriate performance of GUIDANT's Electronic Repositioning™&#xD;
      in the clinical routine with respect to the following major aspects:&#xD;
&#xD;
      avoidance of PNS and low LVP thresholds (for low battery consumption and extended device&#xD;
      longevity) in standard cardiac resynchronization therapy (CRT)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Without the Occurrence of Cardiac Resynchronization Therapy (CRT)-Induced Phrenic Nerve Stimulation (PNS) Between Implant and First Regular Follow-up (FU)</measure>
    <time_frame>From implant until first follow up (occurred between 3 or 6 month after implant procedure)</time_frame>
    <description>The primary endpoint was the percentage of patients in whom PNS induced by Left Ventricular (LV) pacing could be avoided by electronic repositioning from implantation to first regular follow up (3-6 months postimplant). In this evaluation, prevention of PNS was defined as PNS appearing with the standard pacing configuration-LV tip as cathode versus Right Ventricle (RV) coil as anode-and being avoided by at least one of the three alternative reprogrammable configurations.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>LV lead electronically repositioning</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electronic Repositioning</intervention_name>
    <description>Change of pacing vectors for CRT pacing</description>
    <arm_group_label>LV lead electronically repositioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving their FIRST implantation of a Left Ventricular (LV) lead in&#xD;
             combination with a CRT device with implantable cardioverter defibrillator (ICD) backup&#xD;
             and the possibility for Electronic Repositioning™&#xD;
&#xD;
          -  Patients willing (= signed written consent) and capable to participate in all&#xD;
             procedures of the study&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who will not be available for routine Follow up&#xD;
&#xD;
          -  18 years old&#xD;
&#xD;
          -  Known pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>January 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 9, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LV Lead Electronically Repositioning</title>
          <description>Single arm study: Electronic Repositioning: Change of pacing vectors for cardiac resynchronization therapy pacing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292">Number of analyzable patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LV Lead Electronically Repositioning</title>
          <description>Single arm study&#xD;
Electronic Repositioning: Change of pacing vectors for Cardiac Resynchronization Therapy pacing</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Without the Occurrence of Cardiac Resynchronization Therapy (CRT)-Induced Phrenic Nerve Stimulation (PNS) Between Implant and First Regular Follow-up (FU)</title>
        <description>The primary endpoint was the percentage of patients in whom PNS induced by Left Ventricular (LV) pacing could be avoided by electronic repositioning from implantation to first regular follow up (3-6 months postimplant). In this evaluation, prevention of PNS was defined as PNS appearing with the standard pacing configuration-LV tip as cathode versus Right Ventricle (RV) coil as anode-and being avoided by at least one of the three alternative reprogrammable configurations.</description>
        <time_frame>From implant until first follow up (occurred between 3 or 6 month after implant procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inducible PNS @ Max Output 7V / 0.5 ms</title>
            <description>Patients presenting PNS at implant and subsequent follow up (between 3 and 6 months after implant)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without the Occurrence of Cardiac Resynchronization Therapy (CRT)-Induced Phrenic Nerve Stimulation (PNS) Between Implant and First Regular Follow-up (FU)</title>
          <description>The primary endpoint was the percentage of patients in whom PNS induced by Left Ventricular (LV) pacing could be avoided by electronic repositioning from implantation to first regular follow up (3-6 months postimplant). In this evaluation, prevention of PNS was defined as PNS appearing with the standard pacing configuration-LV tip as cathode versus Right Ventricle (RV) coil as anode-and being avoided by at least one of the three alternative reprogrammable configurations.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inducible PNS before Electronic Reprogramming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remaining PNS after Electronic Reprogramming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LV Lead Electronically Repositioning</title>
          <description>Electronic Repositioning: Change of pacing vectors for CRT pacing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Intervention for Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Death - Heart Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Death - Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death (no details)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Syncope - Non cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Death - Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thoracic discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Inappropriate pulse generator Shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Increase of Pacing Threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Ineffective Pulse Generator Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lead Dislodgment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pocket hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lead Replacement - Unknown reason</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary Sinus Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Atrial Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunotheraphy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Elevated Defibrillation Threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Elevated Pacing threshold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lead Dislodgment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pacing system infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pocket Hematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pulse Generator system issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary sinus dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lead - Procedure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joachim Winter, MD</name_or_title>
      <organization>Department of Cardiology and Rhythmology, Augusta Hospital, Duesseldorf, Germany.</organization>
      <phone>+49 (0) 2118 ext 1173</phone>
      <email>joachim.winter@uniklinik-duesseldorf.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

